U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07926048) titled 'A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer' on Oct. 20.
Brief Summary: The goal of this interventional study is to compare the effectiveness and safety of QLS5132 monotherapy with investigator's choice of chemotherapy in participants with platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Intervention:
DRUG: QLS5132
Intravenous infusion, Q3W (Day 1 of each 21-day cycle)...